Skip to content

Immersive Virtual Reality Exergames and Office Workers' Cardiometabolic Health

At-home Immersive Virtual Reality Exergames to Reduce Cardiometabolic Risk Among Office Workers: Protocol for a Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06556784
Enrollment
120
Registered
2024-08-16
Start date
2025-04-30
Completion date
2027-04-30
Last updated
2024-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exergaming, Metabolic Syndrome

Keywords

Immersive virtual reality, Physical activity, Office workers

Brief summary

The worldwide increasing of prevalence of non-communicable diseases has grown the recognition of necessity for identifying the modifiable risk in preventing and managing these diseases. While, the office worker, as a representative group of physical inactivity, is exposed to risk factor of metabolic syndrome which is considered as the pathway of non-communicable diseases. This study mainly focuses on the purpose of examining the interventional efficacy of at-home immersive virtual reality exergame on several metabolic syndrome biomarkers among office workers. In addition, it purposes to determine the impacts of at-home immersive virtual reality exergame on lifestyle pattern of office workers. A 2-armed, single blinded randomized controlled trial (RCT) will be applied to examine the therapeutic effects of at-home immersive virtual reality exergame in this exploratory study. 120 Japanese office workers with less than 150 minutes per week of moderate to vigorous sports activities will be recruited by a convenience sample method. They are randomly allocated to two parallel groups, which including an intervention group: 12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2, a control group: 12-week of maintaining regular exercise, eating, and working habits without making significant changes. During this 12-week trial, 3 main follow up steps are included at the timelines of 0 week, 6 weeks, 12 weeks. For each follow up, we will collect three types of variables, including major clinical risk factors of metabolic syndrome, lifestyle pattern factors of metabolic syndrome, and demographics (0 week only). To analysis the variance between intervention group and control group, mixed linear model will be applied to understand the efficacy result of this intervention. The variances of metabolic syndrome clinical risk factors between groups would be used to express the therapeutic effects of at-home immersive virtual reality exergame. The changes of lifestyle pattern factors would be applied to show the impacts of at-home immersive virtual reality exergame on lifestyle pattern.

Interventions

BEHAVIORAL12-week at-home immersive virtual reality exergame

12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.

Sponsors

Guangzhou University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

The trial will be conducted in a single-blinded structure, ensuring that all the participants are blinded to treatment or control related information. The experiment coordinators are unblinded and responsible for labelling the groups, allocating experimental equipment and materials, gathering data from participants and clinics, and analyzing all the relationships between and within the two groups.

Intervention model description

A 2-armed, single blinded randomized controlled trial (RCT) will be applied to examine the therapeutic effects of at-home immersive virtual reality exergame in this exploratory study.

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-64 years old * Capable of standing and exercising. * Having no history of diagnosis of heart disease, cancer, or dementia. * Being interested in playing with the exergames. * Willingness of adhering to a 12-week interventional exergame treatment.

Exclusion criteria

* Individuals who are already engaged in more than 150 minutes per week of moderate to vigorous activities. * Individuals with some pharmacological treatments, some surgery (bariatric surgery), and some traditional Chinese medicine.

Design outcomes

Primary

MeasureTime frameDescription
Body mass indexBaseline (0 week), Mid-follow up (6-week), Final follow up (12-week).Weight and height will be combined to report body mass index in kg/m\^2.
TriglyceridesBaseline (0 week), Mid-follow up (6-week), Final follow up (12-week).Triglycerides concentration \> 150 mg/dl.
HypertensionBaseline (0 week), Mid-follow up (6-week), Final follow up (12-week).a Systolic blood pressure \> 140 mmHg AND diastolic blood pressure \< 90 mmHg.
High-density lipoprotein cholesterol (HDL-C)Baseline (0 week), Mid-follow up (6-week), Final follow up (12-week).HDL-C concentration less than 35 mg/dl for men (39 mg/dl for women).
Low-density lipoprotein cholesterol (LDL-C)Baseline (0 week), Mid-follow up (6-week), Final follow up (12-week).LDL-C \< 160 mg/dl
Impaired fasting glucoseBaseline (0 week), Mid-follow up (6-week), Final follow up (12-week).a fasting plasma glucose (FPG) concentration between 6.1 and 6.9 mmol/l.

Secondary

MeasureTime frameDescription
Sedentary timeBaseline (0 week, self estimation), Mid-follow up (1-6 week), Final follow up (7-12 week).Total minutes of sedentary time per week.
Exercise time (including exergaming time)Baseline (0 week, self estimation), Mid-follow up (1-6 week), Final follow up (7-12 week).Total minutes of exercise time and exergaming time per week.

Contacts

Primary ContactJing Zhao, PhD
zhaojing@gzhu.edu.cn+86-13170322723
Backup ContactJiuling Li, Masters
hebitoto123@gmail.com+81-7083895217

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026